Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P86 - Targeted Therapy - Clinically Focused - New Target
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P86.08 - Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors
00:00 - 00:00 | Presenter: Alison M Schram
- Abstract
Loading...
-
+
OA04 - New Data from Rare EGFR Alterations
- 11:45 - 12:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Targeted Therapy - Clinically Focused
-
+
OA04.05 - Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
12:05 - 12:15 | Presenter: Kazuhiko Nakagawa
- Abstract
Loading...
-
+
PS01 - Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)
- 07:00 - 09:00
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PS01.05 - Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
07:30 - 07:40 | Presenter: Jay M. Lee
- Abstract
Loading...
-
+
PS02 - Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available)
- 18:00 - 20:00
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PS02.05 - Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
18:30 - 18:40 | Presenter: Jay M. Lee
- Abstract
Loading...
-
+
MA11 - Expanding Targetable Genetic Alterations in NSCLC
- 14:15 - 15:15
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Targeted Therapy - Clinically Focused
-
+
MA11.03 - Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01
14:15 - 14:20 | Presenter: Egbert F Smit
- Abstract
Loading... -
+
MA11.07 - Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
14:35 - 14:40 | Presenter: Byoung Chul Cho
- Abstract
Loading...
-
+
ES28 - Targeting KRAS
- 15:30 - 16:30
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Targeted Therapy - Clinically Focused
-
+
ES28.04 - Emerging Mechanisms to Target KRAS Directly
16:06 - 16:18 | Presenter: Misako Nagasaka
- Abstract
Loading...
